Cite
HARVARD Citation
Lukas, M. et al. (2022). A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts. Scandinavian journal of gastroenterology. pp. 814-824. [Online].